Drug Trial Radar · NCT04262466
Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors
Last checked: Nov 19, 2026Latest source record: Mar 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
410
Actual
Start
Feb 25, 2020
Primary completion
Oct 2026
Study completion Dec 2027
Sponsor
- Lead sponsor
- Immunocore LtdIndustry
- Sponsor type
- Industry
- First posted
- Feb 10, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Brenetafusp (IMC-F106C) is an immune-mobilizing monoclonal T cell receptor against cancer (ImmTAC ®) designed for the treatment of cancers positive for the tumor-associated antigen PRAME. This is a first-in-human trial designed to evaluate the safety and efficacy of brenetafusp in adult participants who have the appropriate HLA-A2 tissue marker and whose cancer is positive for PRAME.
Conditions
- Select Advanced Solid Tumors
Interventions
BrenetafuspDrug
Brenetafusp IV infusions
Brenetafusp and pembrolizumabDrug
Brenetafusp and pembrolizumab IV infusions
Brenetafusp and chemotherapyDrug
Brenetafusp and chemotherapy IV infusions
Brenetafusp and monoclonal antibodies and chemotherapyDrug
Brenetafusp and a monoclonal antibody therapy and chemotherapy
Brenetafusp and tebentafuspDrug
Brenetafusp and tebentafusp IV infusions
Brenetafusp and bevacizumabDrug
Brenetafusp and bevacizumab IV infusions
Brenetafusp and kinase inhibitorsDrug
Brenetafusp and oral kinase inhibitors
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1: Incidence of dose-limiting toxicity (DLT)sTime frame: Up to ~28 days after each dose
- Phase 1: Incidence of adverse events (AE) and serious adverse events (SAE)Time frame: Up to 30 days after the last dose of study therapy
- Phase 1: Number of participants with dose interruptions, dose reductions, or dose discontinuationsTime frame: Up to ~12 months
- Phase 1: Number of participants with abnormal laboratory test results (hematology)Time frame: Up to 30 days after the last dose of study therapy
- Phase 1: Number of participants with abnormal laboratory test results (chemistry)Time frame: Up to 30 days after the last dose of study therapy
- Phase 1: Number of participants with abnormal laboratory test results (coagulation)Time frame: Up to 30 days after the last dose of study therapy
- Phase 1: Number of participants with abnormal urinalysisTime frame: Up to 30 days after the last dose of study therapy
- Phase 1: Number of participants with abnormal vital signsTime frame: Up to 30 days after the last dose of study therapy
- Phase 1: Mean change from baseline in QTcF intervalTime frame: Up to 30 days after the last dose of study therapy
- Phase 2: Best overall response (BOR)Time frame: Up to ~2 years
Locations
76 sites in 17 countries. Site status is shown where the registry gives one.
University of California - San Diego
La Jolla, California
Angeles Clinic and Research Institute
Los Angeles, California
University of California Davis Comprehensive Center
Sacramento, California
University of Colorado
Aurora, Colorado
Georgetown University Medical Center
Washington D.C., District of Columbia
Houston Lee Moffitt Cancer Center & Research Institute
Tampa, Florida
The University of Chicago Medical Center
Chicago, Illinois
University of Iowa
Iowa City, Iowa
Massachusetts General Hospital
Boston, Massachusetts
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey
Columbia University Medical Center
New York, New York
Memorial Sloan Kettering
New York, New York
University of Oklahoma Peggy and Charles Stephenson Cancer Center
Oklahoma City, Oklahoma
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania
Prisma Health
Greenville, South Carolina
Sarah Cannon Research Institute
Nashville, Tennessee
MD Anderson Cancer Center
Houston, Texas
University of Utah - Huntsman Cancer Institute
Salt Lake City, Utah
University of Washington - Fred Hutchinson Cancer Center
Seattle, Washington
University of Wisconsin
Madison, Wisconsin
Scientia Clinical Research
Randwick, New South Wales, Australia
Melanoma Institute Australia (MIA) - The Poche Centre
Wollstonecraft, New South Wales, Australia
The Alfred Hospital
Melbourne, Victoria, Australia
Linear Clinical Research
Nedlands, Western Australia, Australia
LKH - Universitätsklinikum der PMU Salzburg
Salzburg, Austria
Institut Jules Bordet
Brussels, Belgium
UZA
Edegem, Belgium
Universitair Ziekenhuis Gent
Ghent, Belgium
UZ Leuven
Leuven, Belgium
Universitair Ziekenhuis Brussel
Jette, Brussels Capital, Belgium
CHU de Liege
Liège, Luik, Belgium
Hospital Nossa Senhora da Conceicao
Porto Alegre, Brazil
D'Or Institute for Research and Education
Rio de Janeiro, Brazil
National Cancer Institute
Rio de Janeiro, Brazil
Hospital Israelita Albert Einstein
São Paulo, Brazil
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
CHUM Centre de Recherche
Montreal, Quebec, Canada
Hopital Saint-Louis - Centre d'Onco-Dermatologie
Paris, France
Showing 40 of 76 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.